Maintained improvement in physician- and patient-reported outcomes with baricitinib in adults with moderate-to-severe atopic dermatitis who were treated for up to 104 weeks in a randomized trial

• Главные авторы: Jacob P. Thyssen (Автор), Thomas Werfel (Автор), Sebastien Barbarot (Автор), Hamish J.A Hunter (Автор), Evangeline Pierce (Автор), Luna Sun (Автор), Lisa Cirri (Автор), Andrew S. Buchanan (Автор), Na Lu (Автор), Andreas Wollenberg (Автор)
• Формат: ‌
• Опубликовано: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Background Patients who completed the originating studies, BREEZE-AD1 (NCT03334396), BREEZE-AD2(NCT03334422), and BREEZE-AD7 (NCT03733301), were eligible for enrollment in the multicenter,phase-3, long-term extension study BREEZE-AD3 (NCT03334435). Methods At week 52, responders and partial responde...